Application of small-molecule inhibitor HA15 in resisting hepatitis B virus
Compound HA15 reduces the levels of HBsAg, HBeAg, and HBVDNA in the hepatitis B infection model by inhibiting the ATPase activity of HSPA5, and solves the drug resistance and side effects of existing hepatitis B treatment drugs, providing new for hepatitis B. Treatment options and can be combined with other drugs to enhance the effect.
Patent Information
- Application Number
- CN202411019142.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-12
AI Technical Summary
The existing hepatitis B treatment drugs have problems such as virus resistance, long treatment courses, and large side effects, which are difficult to achieve clinical cure, and lack effective new mechanisms or new target drugs.
As an effective inhibitor of the endoplasmic reticulum stress-related protein HSPA5, the compound HA15 reduces the levels of HBsAg, HBeAg, and HBVDNA in the hepatitis B infection model by inhibiting the ATPase activity of HSPA5 and inducing early endoplasmic reticulum stress, as a new Hepatitis B treatment candidate.
HA15 significantly reduced the levels of HBsAg, HBeAg, and HBVDNA in the hepatitis B infection model, and has no toxic side effects on cells and the body under viral inhibition concentration, and has the potential to further develop into hepatitis B therapeutic drugs, providing new for hepatitis B. Treatment options and can be combined with other anti-hepatitis B drugs to enhance antiviral effects.
Smart Images

Figure CN118924744A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to an application of a small molecule inhibitor HA15 in anti-hepatitis B virus. Background Art
[0002] Hepatitis B virus (HBV) infection is an important global health issue. Studies have shown that more than 2 billion people worldwide have experienced or are currently experiencing HBV infection. According to statistics from the World Health Organization, in 2019, approximately 296 million people worldwide were chronically infected (positive for hepatitis B surface antigen (HBsAg)), and the number increases by approximately 1.5 million people each year.
[0003] Hepatitis B virus infection can cause a variety of liver diseases, including acute hepatitis, fulminant hepatic failure, chronic hepatitis, cirrhosis, and hepatocellular carcinoma. More than 90% of infected adults will spontaneously recover from acute hepatitis, but individuals who cannot clear HBsAg in their serum will eventually develop chronic hepatitis B infection (CHB). Chronic HBV infection is characterized by the body's adaptive immune response to the virus, which is difficult to completely eliminate the viral infection. Studies have shown that this special situation is likely due to the tolerance characteristics of the liver microenvironment that inhibit the antiviral immune response. Once a chronic infection is formed, the persistent inflammatory response caused by T lymphocytes and nonspecific inflammatory cells will significantly increase the risk of liver diseases such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
[0004] At present, the main drugs for clinical treatment of hepatitis B are nucleoside analogs and immunomodulators. Nucleoside analogs have problems such as viral resistance, poor viral antigen response, and long treatment course (lifelong medication), making it difficult to achieve clinical cure. Immunomodulators (mainly including thymosin and interferon) are suitable for a small number of people and have large side effects. Due to the limitations of existing clinical treatment drugs, finding new anti-HBV mechanisms or new target drugs has become an important direction for the research and development of anti-HBV drugs at home and abroad. Summary of the invention
[0005] HA15 is an effective and specific inhibitor of the endoplasmic reticulum stress-related protein HSPA5, which inhibits the ATPase activity of HSPA5 and induces early endoplasmic reticulum stress. Previous studies have shown that HA15 inhibits tumor growth through autophagy and apoptosis triggered by endoplasmic reticulum stress, and studies have shown that this inhibitor plays a role in anti-tumor effects.
[0006] In order to solve the problems existing in the treatment of hepatitis B, the present invention has studied and discovered for the first time the effect of compound HA15 in resisting hepatitis B virus. The compound can reduce the levels of HBsAg, HBeAg, and HBVDNA in various hepatitis B infection models; combined with the results of cytotoxicity experiments, HA15 at virus inhibition concentrations does not produce toxic side effects on cells and the body. Therefore, the compound has the potential to be further developed into a candidate drug for the treatment of hepatitis B, providing a new drug option for the treatment of hepatitis B. Based on this, the present invention provides the following technical solutions.
[0007] The first aspect of the present invention provides the use of compound HA15 in the preparation of a medicament for treating hepatitis B, wherein
[0008]
[0009] The compound HA15 has a structural formula as shown in Formula I.
[0010] Furthermore, the drug is a drug for reducing the level of hepatitis B surface antigen HBsAg.
[0011] Furthermore, the drug is a drug for reducing the level of hepatitis B e antigen HBeAg.
[0012] Furthermore, the drug is a drug that reduces the replication level of hepatitis B virus deoxyribonucleic acid HBVDNA.
[0013] Furthermore, the drug comprises compound HA15 as an active ingredient, and pharmaceutically acceptable excipients.
[0014] Furthermore, the pharmaceutically acceptable excipients include diluents, fillers, binders, disintegrants, lubricants, solvents, solubilizers, co-solvents, emulsifiers and / or colorants.
[0015] Furthermore, the pharmaceutically acceptable excipients include microcrystalline cellulose, cellulose acetate phthalate (CAP), sodium carboxymethyl cellulose (CMCNa), ethyl cellulose (EC), hydroxypropyl methyl cellulose (HPMC), and the like.
[0016] Furthermore, the dosage forms of the drug include tablets, powders, granules, capsules, emulsions, solutions, suspensions, injections, etc.
[0017] Furthermore, the drug is used alone or in combination.
[0018] Furthermore, the combination therapy is the combination of the drug and entecavir (ETV).
[0019] The second aspect of the present invention provides the use of compound HA15 in anti-hepatitis B virus, wherein
[0020]
[0021] The compound HA15 has a structural formula as shown in Formula I.
[0022] Furthermore, the application includes preventing hepatitis B virus infection, inhibiting hepatitis B virus replication, blocking hepatitis B virus transmission, and alleviating clinical symptoms of hepatitis B.
[0023] Furthermore, the application includes reducing the level of hepatitis B surface antigen HBsAg.
[0024] Furthermore, the application includes reducing the level of hepatitis B e antigen HBeAg.
[0025] Furthermore, the application includes reducing the replication level of hepatitis B virus deoxyribonucleic acid HBVDNA.
[0026] Furthermore, the application includes the use of HA15 alone or in combination with other anti-hepatitis B virus compounds.
[0027] Furthermore, the other anti-hepatitis B virus compound is entecavir (ETV).
[0028] The beneficial effects of the present invention include:
[0029] 1. The present invention is the first to study and discover the effect of compound HA15 in anti-hepatitis B virus. The compound can reduce the levels of HBsAg, HBeAg, and HBVDNA in various hepatitis B infection models. Combined with the results of cytotoxicity experiments, HA15 at the virus inhibition concentration will not produce toxic side effects on cells and the body.
[0030] 2. This compound can be used in combination with other anti-hepatitis B virus compounds to achieve a better antiviral effect.
[0031] 3. This compound has the potential to be further developed into a candidate drug for the treatment of hepatitis B, providing a new drug option for the treatment of hepatitis B. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is a schematic diagram of the results of cytotoxicity detection of HA15 on pHBV-HepG2 cells and HepG2.215 cells in one embodiment of the present invention;
[0033] Figure 2This is a schematic diagram of the results of hepatitis B surface antigen detection and hepatitis B e antigen detection of HA15 on pHBV-HepG2 cells and HepG2.215 cells in one embodiment of the present invention;
[0034] Figure 3 This is a schematic diagram of the results of HBV DNA detection by HA15 on pHBV-HepG2 cells and HepG2.215 cells in one embodiment of the present invention;
[0035] Figure 4 This is a schematic diagram of the results of detecting hepatitis B surface antigen, hepatitis B e antigen and HBV DNA by HA15 in an acute hepatitis B infection animal model in one embodiment of the present invention. DETAILED DESCRIPTION
[0036] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0037] The experimental methods in the following examples without specifying the specific conditions are all measured in accordance with national standards; the experimental materials in the following examples without specifying the source are all commercially available raw materials. The equipment used in each step in the following examples is conventional equipment. If there is no corresponding national standard, it is carried out according to the general international standards, conventional conditions, or according to the conditions recommended by the manufacturer. Unless otherwise specified, all parts are parts by weight and all percentages are mass percentages. Unless otherwise defined or specified, all professional and scientific terms used in the present invention have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equal to the recorded content can be applied to the method of the present invention.
[0038] In order to clarify the mechanism of drug action, the cell models used in this technical solution include: pHBV-HepG2 (HepG2 liver cancer cells transfected with pHBV1.2 plasmid) and HepG2.215 (liver cancer cells infected with HBV). pHBV1.2 plasmid and HepG2.215 cells were donated by Academician Wen Yumei of Fudan University, and HepG2 liver cancer cells were from the cell bank of the Chinese Academy of Sciences.
[0039] In the following examples, the reagents used include: DMEM high-glucose culture medium, penicillin-streptomycin double antibody, dimethyl sulfoxide (DMSO), and Tween 80 purchased from Dalian Meilun Company; CCK8 kit, gbico fetal bovine serum, and lipo6000 transfection reagent purchased from Shanghai Biyuntian Company; HA15 and PEG300 purchased from MCE Company; HBeAg and HBsAg detection kits purchased from Shanghai Kehua Company; HBV-DNA detection kit purchased from Shengxiang Biotechnology.
[0040] Example 1
[0041] HA15 cytotoxicity assay
[0042] In this example, the cytotoxicity of HA15 was detected, and the detection experimental steps were as follows:
[0043] Take HepG2 and HepG2.215 cells with good growth status, digest them with trypsin, centrifuge at 250g for 3min, add fresh DMEM complete medium to resuspend the cells, take 18μL of cell suspension, add 2μL of 4% trypan blue solution and mix well, add to the cell counting plate and detect the cell density on the cell counter. Use DMEM complete medium to dilute the cell density to 2×10 5 / mL, 100 μL per well was inoculated in a 96-well plate. Incubate at 37°C, 5% CO 2 The cells were cultured in an incubator for 24 hours. DMEM complete medium containing different concentrations of drugs was added, and after 48 hours of drug incubation, the cell viability was detected using the CCK-8 method to determine the effect of the drugs on cell proliferation activity.
[0044] CCK-8 detection steps: After 48 hours of drug incubation, add 10 μL of CCK-8 solution to each well of the 96-well plate and shake gently to mix thoroughly. Continue incubation in a 37°C cell culture incubator for 30 minutes, and use an ELISA reader to detect the absorbance of each well at 450nm (reference wavelength is 630nm), and calculate the effect of each concentration of drug on cell growth based on the absorbance.
[0045] The above CCK-8 experimental results are as follows Figure 1 Shown .
[0046] The above experimental results show that HA15 has almost no cytotoxicity to HepG2 and HepG2.215 cells at low concentrations (5μM / 10μM). Based on the above experimental results, 5μM / 10μM will be used as the drug experimental concentration in the following experiments.
[0047] Example 2
[0048] HA15 inhibits hepatitis B surface antigen (HBsAg) and hepatitis B e antigen in pHBV-HepG2 and HepG2.215 cell infection models Study on the effect of HBeAg level
[0049] This example studies the effect of HA15 on antigen secretion and expression in a hepatitis B cell model, and the experimental steps are as follows:
[0050] Take HepG2 cells with good growth status, digest them with trypsin, centrifuge at 250g for 3min, add fresh DMEM complete medium to resuspend the cells, take 18μL of cell suspension, add 2μL of 4% trypan blue solution and mix well, add to the cell counting plate and detect the cell density on the cell counter. Use DMEM complete medium to dilute the cell density to 2×10 5 / mL, 500 μL per well was inoculated in a 24-well plate. After 24 hours of culture, the medium was replaced with complete DMEM without antibiotics.
[0051] Take two sterile and clean centrifuge tubes, add DMEM culture medium (without serum and antibiotics) and mark them as tube A and tube B respectively. Add lipo6000 transfection reagent to tube A and pHBV1.2 plasmid to tube B, gently blow and mix thoroughly. After standing at room temperature for 5 minutes, add the solution in tube B to tube A, gently blow and mix thoroughly (do not vortex). Stand at room temperature for 5 minutes, and evenly add the mixed solution to the culture plate according to the amount of 50μL per well of the 24-well plate, and gently shake the culture plate to mix the liquid thoroughly. Place in 37℃, 5% CO 2 The cells were cultured in a cell culture incubator for 6 hours, then the cell culture medium was discarded, the cells were rinsed twice with PBS solution, and fresh DMEM culture medium containing different concentrations of drugs was added for continued culture. The drug-containing culture medium was replaced every 48 hours. The cell culture supernatant was collected for the detection of HBsAg and HBeAg.
[0052] HBsAg antigen secretion level detection
[0053] (1) Equilibrate the HBsAg test kit to room temperature. Dilute the sample to be tested with PBS solution to an appropriate concentration.
[0054] (2) Add 75 μL of the sample to be tested into the microwell reaction plate, seal the plate with a sealing film, and incubate at 37°C for 1 hour.
[0055] (3) Add 50 μL of enzyme conjugate to the microwells, gently shake to mix, reseal the plate, and incubate at 37°C for 30 min.
[0056] (4) Wash the plate: spin dry the liquid in the wells, add 250 mL of HBsAg washing solution to each well using a spray gun, let it stand for 1 min, then spin dry, repeat 5 times. Then pat dry the liquid in the wells on absorbent paper.
[0057] (5) Calculate the amount of colorimetric solution required based on 50 μL of colorimetric solution A and 50 μL of colorimetric solution B per well, and mix well in advance. Add 100 μL of the mixed colorimetric solution to each well and incubate at 37°C for 30 min (if the color is too dark, terminate the reaction early).
[0058] (6) Add 50 μL of stop solution to each well to terminate the reaction. Use an ELISA reader to measure the absorbance at 450 nm.
[0059] Detection of relative HBeAg content
[0060] (1) Equilibrate the HBV e antigen detection kit to room temperature. Dilute the sample to be tested with PBS solution to an appropriate concentration.
[0061] (2) Add 50 μL of the sample to be tested to the microwell reaction plate, and set up 2 negative control wells (add 50 μL of negative control) and 2 positive control wells (add 50 μL of positive control). Then add 50 μL of enzyme conjugate to the microwells, shake gently to mix, seal the plate with a sealing film, and incubate at 37°C for 30 min.
[0062] (3) Wash the plate: spin dry the liquid in the wells, add 250 μL of HBeAg washing solution to each well using a spray gun, let stand for 15 seconds and spin dry, repeat 5 times. Then pat dry the liquid in the wells on absorbent paper.
[0063] (4) Calculate the amount of colorimetric solution required based on 50 μL of colorimetric solution A and 50 μL of colorimetric solution B per well, and mix well in advance. Add 100 μL of the mixed colorimetric solution to each well and incubate at 37°C for 30 min (if the color is too dark, terminate the reaction early).
[0064] (5) Add 50 μL of stop solution to each well to terminate the reaction. Use an ELISA reader to measure the absorbance at 450 nm.
[0065] The above experimental results are as follows Figure 2 Shown .
[0066] The above experimental results showed that the administered concentration of HA15 significantly inhibited the expression levels of HBsAg and HBeAg, and had an obvious dose-effect relationship.
[0067] Example 3
[0068] Study on the effect of HA15 on HBV-DNA level in pHBV-HepG2 and HepG2.215 cell infection models
[0069] In this example, the effect of HA15 on the secretion of HBV virus particles was studied in a hepatitis B cell model by detecting the content of HBV-DNA in the cell supernatant. The experimental steps are as follows:
[0070] Sample preparation:
[0071] Take out the sample release agent, balance to room temperature, and add 5 μL of sample release agent to each well of the PCR plate. Add 5 μL of the sample to be processed (cell supernatant) to each well, pipette 3-5 times to mix, and let it stand for 10 minutes before use.
[0072] PCR-fluorescent probe method for HBV-DNA detection:
[0073] (1) Take out the components of the HBV-DNA detection kit and equilibrate them to room temperature.
[0074] (2) According to the number of samples to be tested, negative control, positive control and quantitative reference substance AD, take the corresponding amount of reaction solution, enzyme mixture and internal standard in proportion (reaction solution 38 μL / well + enzyme mixture 2 μL / well + internal standard 0.2 μL / well), mix them thoroughly to form PCR mixture, centrifuge briefly and set aside.
[0075] (3) Add 40 μL of PCR mixture to each well of the sample wells prepared above, seal the plate, and detect with RT-PCR instrument. Select FAM channel (Reporter: FAM, Quencher: none) to detect HBV-DNA; select HEX / VIC channel (Reporter: HEX / VIC; Quencher: none) to detect HBV internal standard; set reference fluorescence to ROX.
[0076] (4) Calculate the standard curve based on the CT value of the quantitative reference sample AD and calculate the HBV-DNA content in each sample to be tested.
[0077] PCR procedure:
[0078] (1) UNG enzyme reaction: 50°C, 1 min.
[0079] (2) Taq enzyme activation: 94°C, 5 min.
[0080] (3) Amplification cycles: 94°C, 15 sec; 57°C, 30 sec, for a total of 45 cycles.
[0081] The experimental results are as follows Figure 3 shown.
[0082] According to the experimental results, HA15 significantly reduced the content of HBV-DNA in the cell supernatant and inhibited the secretion of hepatitis B virus particles. Moreover, when used in combination with entecavir (ETV), it had a better antiviral effect.
[0083] Example 4
[0084] Study on the effect of HA15 on the levels of HBsAg, HBeAg and HBV-DNA in acute animal models of hepatitis B
[0085] In this example, the anti-HBV efficacy of HA15 in vivo was studied in a hepatitis B animal model by detecting the levels of HBsAg, HBeAg and HBV-DNA in serum. The experimental steps are as follows:
[0086] An acute HBV infection animal model was constructed by high-pressure injection of pHBV1.2 plasmid into the tail vein of Balb / c mice (purchased from Shanghai Shengchang Biotechnology Co., Ltd.). When the average weight of the mice reached about 20-22g, it was recorded as day 0, and 2mL of pHBV1.2 plasmid dissolved in PBS (concentration of 10μg / mouse) was injected into the tail vein of the mice on the same day. On the second day after the modeling was completed, orbital blood was collected from each mouse, and the HBsAg content in the serum was measured. The animals were divided into 4 groups according to the HBsAg antigen content to ensure that the average HBsAg antigen content in the serum of each group of mice was similar and there was no significant difference. For the next 6 days, 0.2ml of HA15 with a concentration of 0.5mg / kg was given to the mice every day by intraperitoneal injection (injection formula: 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline), and an entecavir-positive drug control group was used. The mice were killed on the 7th day, and the serum was collected for experimental analysis.
[0087] The experimental results are as follows Figure 4 shown.
[0088] According to the experimental results, HA15 significantly reduced the HBV-DNA content in serum, inhibited the secretion of hepatitis B virus particles, and also had a certain degree of inhibitory effect on antigens.
[0089] In summary, the present invention provides the use of compound HA15 in the preparation of a drug for treating hepatitis B and its application in resisting hepatitis B virus. A series of experiments have shown that HA15 can significantly reduce the levels of HBsAg, HBeAg, and HBV-DNA in cells infected with HBV, and has a wide range of application prospects in resisting hepatitis B virus.
[0090] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may alter, modify, replace and modify the above embodiments within the scope of the present invention.
Claims
1. Use of compound HA15 in the preparation of a medicament for treating hepatitis B, wherein The compound HA15 has a structural formula as shown in Formula I.
2. The use according to claim 1, It is characterized in that The drug is a drug for reducing the level of hepatitis B surface antigen HBsAg.
3. The use according to claim 1, It is characterized in that The drug is a drug for reducing the level of hepatitis B e antigen HBeAg.
4. The use according to claim 1, It is characterized in that The drug is a drug for reducing the replication level of hepatitis B virus deoxyribonucleic acid HBVDNA.
5. The use according to any one of claims 1 to 4, It is characterized in that The medicine comprises compound HA15 as an active ingredient and pharmaceutically acceptable excipients.
6. The use according to claim 5, It is characterized in that The pharmaceutically acceptable excipients include diluents, fillers, binders, disintegrants, lubricants, solvents, solubilizers, co-solvents, emulsifiers and / or colorants.
7. The use according to any one of claims 1 to 4, It is characterized in that The dosage form of the drug includes tablets, powders, granules, capsules, emulsions, solutions, suspensions or injections.
8. The use according to any one of claims 1 to 4, It is characterized in that The medicine is used alone or in combination.
9. The use according to claim 8, It is characterized in that The combined drug is the combined use of the drug and entecavir.
10. Use of compound HA15 in anti-hepatitis B virus, wherein The compound HA15 has a structural formula as shown in Formula I.
Citation Information
Patent Citations
Methods and compositions for intranasal delivery
CN103126996A
Inhibitor for regulating and controlling secretion of anti-hepatitis B virus particles by GRP78
CN113995829A
Application of GRp78 inhibiting reagent in preparation of medicine for treating and / or preventing liver cancer caused by HBV rtA181T / sW172*
CN118121705A
Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
US20110212127A1
